Search KLH Site
Find Articles by Tags
Addiction (18) Adjuvant - Alum (1) Adjuvant - GPI-0100 (1) Adjuvant - IL-4 (9) Adjuvant GM-CSF (16) Adjuvant KLH (4) Adjuvant Oil / Surfactant (4) Adjuvant QS-21 (25) Age & Physical Activity (3) Allergen-specific immunotherapy (1) Allergy – Pollen (2) Alzheimer's Disease (3) Antibody Response (35) Antibody Response IgA (14) Antibody Response IgE (6) Antibody Response IgG (106) Antibody Response IgM (71) Antibody Response IgY (1) APEC (1) Assay - Bioassay (2) Assay - Carbohydrate Microarray (1) Assay - ELISA (55) Assay - ELISPOT (7) Assay - Immunoassay (8) Assay - InVitro (18) Assay - InVivo (1) Atopic Dermatitis (1) Autoimmune Disease (1) B-epitope (1) Bone Marrow Transplant (6) Cancer (6) Cancer - Bladder (16) Cancer - Brain & CNS (8) Cancer - Breast (15) Cancer - Cervical (1) Cancer - Colorectal (10) Cancer - Esophageal (1) Cancer - Female Reproductive (7) Cancer - Leukemia (2) Cancer - Lung (4) Cancer - Lymphoma (25) Cancer - Melanoma (37) Cancer - Mesothelioma (1) Cancer - Myeloma (15) Cancer - Other (2) Cancer - Ovarian (3) Cancer - Pancreas (1) Cancer - Pediatric (3) Cancer - Peritoneal (2) Cancer - Prostate (9) Cancer - Renal (13) Cancer - Sarcoma (2) Clostridium difficile (5) Crohn's Disease (2) Cross-Reactive Antigens (6) Delayed-type hypersensitivity response (1) Dendritic Cell (66) Developmental (10) Diabetes (2) Disease Resistence (1) DNP-Ficoll (2) DTH (67) Environmental (15) Escherichia coli (1) Fingolimod (Gilenya) (1) Healthy Volunteers (18) HealthyAntibody Response - IgA (1) Hepatitis (2) HIV (11) HPV (3) Husbandry (3) Hypertension (1) id-KLH (29) IL 1 (4) IL 12 (2) IL 15 (1) IL 2 (10) IL 5 (1) IL 6 (1) IL 7 (1) Immune Disease - Autoimmune (13) Immune Disease - Primary (2) Immune Disease – Secondary (1) Immune Response - Cellular (187) Immune Response - Humoral (259) Immune Response Humoral (2) Immunotoxicity (37) Infection (1) Infectious Disease (5) Inflammatory Disease (1) Intradermal KLH (1) Kidney (1) KLH-BEC2 (1) KLH-BP16 (1) KLH-BPO (1) KLH-Conjugate (69) KLH-EGFR (2) KLH-FITC (1) KLH-Ganglioside (16) KLH-Globo H (7) KLH-GM2 (1) KLH-hD1 (1) KLH-HGP-30 (1) KLH-IL (1) KLH-Kinoid (8) KLH-Lewis Y (3) KLH-MUC (8) KLH-Oxycodone (2) KLH-sTn (9) KLH-TF (5) KLH-TN (3) Model - Canine (6) Model - Guinea Pig (10) Model - Livestock (10) Model - Mouse (73) Model - Other (32) Model - Primate (12) Model - Rat (51) Multiple Sclerosis (1) Nasal (3) Natrural Antibody (1) Neonatal (2) NK Cells (1) NSAID (1) Oral KLH (9) Oxycodone (3) Parasitic Disease (6) Pediatric (1) Plant-made (2) PLNA (1) Population Density (3) Psoriasis (1) Review Article (2) Rheumatoid Arthritis (11) Rituximab (Rituxan) (4) Russian thistle (1) Sal k 1 (1) Stress (8) Systemic Lupus Erythematosus (SLE) (7) TACA (2) TDAR (127) Therapeutics - KLH Alone (15) Transplant (6) Ultra Violet radiation (1) Uveitis (1) VEGF (3) Veterinary (1)
Terms and Privacy

KLH in Publications

Publications of scientific research involving KLH. Abstracts or full text articles are available by link to outside sites. If you know of a KLH-related publication that is not yet on KLH Site™, let us know.

(in order by date)

Entries in Cancer - Bladder (16)

Friday
Nov302012

Vaccination into the Tumor Microenvironment Using Recombinant Vaccinia Expressing HER2/NEU Leads to Tumor Regression and the Generation of a Tumor-specific Systemic T Cell Response in a Mouse Model of HER2/NEU-overexpressing Mammary Carcinoma

Christiaan R. de Vries1, Claude E. Monken2, Edmund C. Lattime3.

1 Department of Microbiology and Molecular Genetics, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ;
2 The Cancer Institute of New Jersey, New Brunswick, NJ;
3 Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ.

Abstracts for the 27th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC);  J Immunotherapy, Vol. 35, No. 9, November–December 2012

Monday
May142012

Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non-Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial.

Lammers RJ, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA

J Clin Oncol. 2012 May 14

 

Monday
Jul112011

Hemocyanins as immunostimulants

Del Campo M, Arancibia S, Nova E, Salazar F, González A, Moltedo B, De Ioannis P, Ferreira J, Manubens A, Becker MI.

Rev Med Chil. 2011 Feb;139(2):236-46. Epub 2011 Jul 11

Thursday
Feb112010

Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray

Friday
Oct012004

Superficial bladder cancer therapy

Emmanuel Schenkman, M.D. and Donald L. Lamm, M.D.

ScientificWorldJ (2004) 4 (S1), 387–399

Wednesday
Oct012003

Laboratory and clinical experience with keyhole limpet hemocyanin (Immucothel(r)) in superficial bladder cancer

Sunday
Oct012000

Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study

Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF.

Eur Urol. 2000;37 Suppl 3:45-9

Friday
Sep012000

Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies

Lamm DL, Dehaven JI, Riggs DR.

Eur Urol. 2000;37 Suppl 3:41-4

Tuesday
Aug012000

Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinoma

Echarti C, Jurincic-Winkler CD, Klippel KF.

Eur Urol. 2000;37 Suppl 3:50-3

Saturday
Jan012000

Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results

Linn JF, Black P, Derksen K, Rübben H, Thüroff JW

Eur Urol. 2000;37 Suppl 3:34-40

Monday
Sep011997

Immunotherapy of bladder cancer

Monday
Jul011996

Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma

Jurincic-Winkler CD, von der Kammer H, Beuth J, Scheit KH, Klippel KF

Anticancer Res. 1996 Jul-Aug;16(4A):2105-10

Friday
Dec011995

Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin.

Jurincic-Winkler C, Metz KA, Beuth J, Engelmann U, Klippel KF.

Br J Urol. 1995 Dec;76(6):702-7.

Sunday
Oct011995

Efficacy of local Bacillus Calmette-Guérin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy.

Jurincic-Winkler C, Engelmann U, Beuth J, Klippel KF

Zentralbl Bakteriol. 1995 Oct;282(4):409-15

Monday
May011995

Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer

Wishahi MM, Ismail IM, Ruebben H, Otto T.

J Urol. 1995 Mar;153(3 Pt 2):926-8

Sunday
Jan011995

Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder

Jurincic-Winkler CD, Gallati H, Alvarez-Mon M, Sippel J, Carballido J, Klippel KF

Eur Urol. 1995;28(4):334-9